SCHEMBL3510101

SCHEMBL3510101

CCOC(=O)c1cnn(CCOC)c1C

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.52
KMT2A Q03164 1/20 0.52
ALDH1A1 P00352 6/20 0.51
KDM4E B2RXH2 2/20 0.51
MAPT P10636 1/20 0.51
CYP3A4 P08684 1/20 0.50
CYP2C19 P33261 1/20 0.50
LMNA P02545 3/20 0.49
NPC1 O15118 2/20 0.47
PAX8 Q06710 1/20 0.46
RAB9A P51151 2/20 0.44
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407148 0.86 NPC1 (0.61) SMN1; SMN2KMT2AALDH1A1KDM4EMAPT
SCHEMBL1406998 0.86 ALDH1A1 (0.49) SMN1; SMN2KMT2AALDH1A1KDM4EMAPT
SCHEMBL3509334 0.85 SMN1; SMN2 (0.54) SMN1; SMN2KMT2AALDH1A1KDM4EMAPT
SCHEMBL13462878 0.83 SMN1; SMN2 (0.58) SMN1; SMN2KMT2AALDH1A1KDM4ECYP2C19
SCHEMBL1407038 0.82 TRPC1 (0.48) SMN1; SMN2KMT2AALDH1A1KDM4EMAPT
SCHEMBL9312267 0.82 KMT2A (0.52) SMN1; SMN2KMT2AALDH1A1KDM4ECYP3A4
SCHEMBL6664950 0.81 SMN1; SMN2 (0.56) SMN1; SMN2KMT2AALDH1A1KDM4EMAPT
SCHEMBL20797210 0.80 SMN1; SMN2 (0.50) SMN1; SMN2KMT2AALDH1A1KDM4EMAPT
SCHEMBL1406952 0.79 NPC1 (0.56) SMN1; SMN2KMT2AALDH1A1KDM4EMAPT
SCHEMBL1407215 0.79 ALDH1A1 (0.46) SMN1; SMN2KMT2AALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299267-B2 (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating COMENTIS, INC. (US) 2012-10-30 US disclosed
US-20100286170-A1 (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING COMENTIS, INC 2010-11-11 US disclosed
US-20100286145-A1 ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY COMENTIS, INC. (US) 2010-11-11 US disclosed
EP-2205596-A1 (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING COMENTIS, INC. (US) 2010-07-14 EP disclosed
EP-2178837-A2 ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY COMENTIS, INC. (US) 2010-04-28 EP disclosed
WO-2009042694-A1 (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING COMENTIS, INC. (US) 2009-04-02 WO disclosed
WO-2009015369-A2 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286145-A1 ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY BACE1, BACE2, APP SMN1; SMN2 2575/4885KMT2A 1493/4885ALDH1A1 1223/4885
US-20100286170-A1 (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING BACE1, BACE2, PSEN1 SMN1; SMN2 2187/4885KMT2A 2623/4885ALDH1A1 1430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.